Your browser doesn't support javascript.
loading
Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease.
Younes, Ramy; Govaere, Olivier; Petta, Salvatore; Miele, Luca; Tiniakos, Dina; Burt, Alastair; David, Ezio; Vecchio, Fabio M; Maggioni, Marco; Cabibi, Daniela; Fracanzani, Anna L; Rosso, Chiara; Blanco, Maria J Garcia; Armandi, Angelo; Caviglia, Gian Paolo; Zaki, Marco Y W; Liguori, Antonio; Francione, Paolo; Pennisi, Grazia; Grieco, Antonio; Valenti, Luca; Anstee, Quentin M; Bugianesi, Elisabetta.
Afiliación
  • Younes R; Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Govaere O; The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Petta S; The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Miele L; Sezione di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy.
  • Tiniakos D; Università Cattolica del Sacro Cuore, Rome, Italy.
  • Burt A; Area Medicina Interna, Gastroenterologia e Oncologia Medica, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.
  • David E; The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Vecchio FM; The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Maggioni M; Department of Pathology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, University of Turin, Turin, Italy.
  • Cabibi D; Università Cattolica del Sacro Cuore, Rome, Italy.
  • Fracanzani AL; Area Anatomia Patologica, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
  • Rosso C; Department of Pathology, Ca' Granda IRCCS Foundation, Milan, Italy.
  • Blanco MJG; Pathology Institute, PROMISE, University of Palermo, Palermo, Italy.
  • Armandi A; Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital, University of Milan, Milan, Italy.
  • Caviglia GP; Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Zaki MYW; Hospital Universitario de La Princesa, Medicina Interna, Madrid, Spain.
  • Liguori A; Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Francione P; Department of Medical Sciences, Division of Gastroenterology and Hepatology, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
  • Pennisi G; The Newcastle Liver Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Grieco A; Biochemistry Department, Faculty of Pharmacy, Minia University, Minya, Egypt.
  • Valenti L; Università Cattolica del Sacro Cuore, Rome, Italy.
  • Anstee QM; Unit of Medicine and Metabolic Disease, Department of Pathophysiology and Transplantation, Ca' Granda IRCCS Foundation, Policlinico Hospital, University of Milan, Milan, Italy.
  • Bugianesi E; Sezione di Gastroenterologia, Dipartimento Biomedico di Medicina Interna e Specialistica, Università di Palermo, Palermo, Italy.
Am J Gastroenterol ; 115(8): 1289-1292, 2020 08.
Article en En | MEDLINE | ID: mdl-32453041
ABSTRACT

INTRODUCTION:

We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD).

METHODS:

ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months.

RESULTS:

Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative.

DISCUSSION:

Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Antinucleares / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Am J Gastroenterol Año: 2020 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Antinucleares / Enfermedad del Hígado Graso no Alcohólico Tipo de estudio: Clinical_trials / Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Am J Gastroenterol Año: 2020 Tipo del documento: Article País de afiliación: Italia